Literature DB >> 25868128

Induction of Pig-a mutant erythrocytes in male and female rats exposed to 1,3-propane sultone, ethyl carbamate, or thiotepa.

Carson Labash1, Kristine Carlson1, Svetlana L Avlasevich1, Ariel Berg1, Jeffrey C Bemis1, James T MacGregor2, Stephen D Dertinger3.   

Abstract

Validation of the Pig-a gene mutation assay has been based mainly on studies in male rodents. To determine if the mutagen-induced responses of the X-linked Pig-a gene differ in females compared to males, groups of five male and female Sprague Dawley rats were exposed to the mutagens 1,3-propane sultone (80mg/kg/day), ethyl carbamate (600mg/kg/day), or thiotepa (7.5mg/kg/day) for three consecutive days (study days 1-3). Pig-a mutant phenotype reticulocyte (RET(CD59-)) and mutant phenotype erythrocyte (RBC(CD59-)) frequencies were determined on study days -4, 15, 30 and 46 using immunomagnetic separation in conjunction with flow cytometric analysis (In Vivo MutaFlow(®)). While the percentage of reticulocytes (%RET) was markedly higher for pre-treatment blood samples from males compared to females (6.6% vs. 3.5%), this sex effect was slight or nonexistent at later time points. Treatment-related effects to %RET were generally modest owing to the 12-day interval between last exposure and blood sampling. Mean RET(CD59-) and RBC(CD59-) frequencies were consistently low in vehicle control animals of both sexes, with 77% of samples exhibiting mutant cell frequencies ≤1×10(-6) over study days 15-46. Treatment with each mutagen caused significant increases to mean RET(CD59-) and RBC(CD59-) frequencies. Whereas genotoxicant-induced RET(CD59-) values were maximal on day 15, induced RBC(CD59-) frequencies were highest at the last sampling time. Sex did not affect 1,3-propane sultone- or thiotepa-induced mutant cell frequencies. While ethyl carbamate-exposed females exhibited higher mean mutant cell frequencies compared to like-treated males, statistical significance was achieved only for RBC(CD59-) at one time point (7.6±1.0×10(-6) compared to 4.7±0.6×10(-6) on day 30). Thus, while some quantitative differences were evident, there were no qualitative differences in how males and females responded to three diverse mutagens. These data support the use of both sexes for Pig-a gene mutation studies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD59; Flow cytometry; In vivo; Mutation assay; Peripheral blood; Sex effect

Mesh:

Substances:

Year:  2015        PMID: 25868128      PMCID: PMC4395863          DOI: 10.1016/j.mrgentox.2015.03.011

Source DB:  PubMed          Journal:  Mutat Res Genet Toxicol Environ Mutagen        ISSN: 1383-5718            Impact factor:   2.873


  18 in total

1.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.

Authors:  D J Araten; K Nafa; K Pakdeesuwan; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Interlaboratory Pig-a gene mutation assay trial: Studies of 1,3-propane sultone with immunomagnetic enrichment of mutant erythrocytes.

Authors:  Stephen D Dertinger; Souk Phonethepswath; Pamela Weller; Svetlana Avlasevich; Dorothea K Torous; Jared A Mereness; Steven M Bryce; Jeffrey C Bemis; Sara Bell; Susan Portugal; Michael Aylott; James T MacGregor
Journal:  Environ Mol Mutagen       Date:  2011-08-29       Impact factor: 3.216

3.  Sex difference in the micronucleus test. The Collaborative Study Group for the Micronucleus Test.

Authors: 
Journal:  Mutat Res       Date:  1986-11       Impact factor: 2.433

4.  Sex difference in sensitivity to the cytogenetic effects of ethyl methanesulfonate in mice demonstrated by the micronucleus test.

Authors:  M Henry; S Lupo; K T Szabo
Journal:  Mutat Res       Date:  1980-02       Impact factor: 2.433

5.  Integration of mutation and chromosomal damage endpoints into 28-day repeat dose toxicology studies.

Authors:  Stephen D Dertinger; Souk Phonethepswath; Dean Franklin; Pamela Weller; Dorothea K Torous; Steven M Bryce; Svetlana Avlasevich; Jeffrey C Bemis; Ollivier Hyrien; James Palis; James T MacGregor
Journal:  Toxicol Sci       Date:  2010-03-04       Impact factor: 4.849

6.  Glycophosphatidylinositol-anchored protein deficiency as a marker of mutator phenotypes in cancer.

Authors:  R Chen; J R Eshleman; R A Brodsky; M E Medof
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

7.  Effect of ethanol on the tumorigenicity of urethane (ethyl carbamate) in B6C3F1 mice.

Authors:  Frederick A Beland; R Wayne Benson; Paul W Mellick; Robert M Kovatch; Dean W Roberts; Jia-Long Fang; Daniel R Doerge
Journal:  Food Chem Toxicol       Date:  2005-01       Impact factor: 6.023

8.  Integration of Pig-a, micronucleus, chromosome aberration, and Comet assay endpoints in a 28-day rodent toxicity study with 4-nitroquinoline-1-oxide.

Authors:  Leon F Stankowski; Daniel J Roberts; Hepei Chen; Timothy Lawlor; Marie McKeon; Hemalatha Murli; Ajit Thakur; Yong Xu
Journal:  Environ Mol Mutagen       Date:  2011-10-21       Impact factor: 3.216

9.  In vivo mutation assay based on the endogenous Pig-a locus.

Authors:  Steven M Bryce; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2008-05       Impact factor: 3.216

10.  Development of an in vivo gene mutation assay using the endogenous Pig-A gene: I. Flow cytometric detection of CD59-negative peripheral red blood cells and CD48-negative spleen T-cells from the rat.

Authors:  Daishiro Miura; Vasily N Dobrovolsky; Yoshinori Kasahara; Yasuhiro Katsuura; Robert H Heflich
Journal:  Environ Mol Mutagen       Date:  2008-10       Impact factor: 3.216

View more
  1 in total

1.  Standard protocol for the total red blood cell Pig-a assay used in the interlaboratory trial organized by the Mammalian Mutagenicity Study Group of the Japanese Environmental Mutagen Society.

Authors:  Satsuki Chikura; Takafumi Kimoto; Satoru Itoh; Hisakazu Sanada; Shigeharu Muto; Katsuyoshi Horibata
Journal:  Genes Environ       Date:  2019-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.